Alimta pemetrexed regulatory update

The U.K.'s NICE issued final guidance recommending against the use of Alimta pemetrexed from Eli Lilly for maintenance treatment of locally advanced or metastatic, non-squamous non-small-cell lung cancer (NSCLC) in patients whose disease has not immediately progressed following induction therapy with Alimta and cisplatin. The guidance is in line with a February final appraisal determination (FAD) (see BioCentury, March 3). ...